Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by James Hambro & Partners LLP

James Hambro & Partners LLP cut its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 7.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 224,066 shares of the medical equipment provider's stock after selling 18,556 shares during the period. Intuitive Surgical makes up 4.6% of James Hambro & Partners LLP's holdings, making the stock its 13th biggest holding. James Hambro & Partners LLP owned 0.06% of Intuitive Surgical worth $110,957,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Onefund LLC boosted its position in Intuitive Surgical by 1.9% in the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock valued at $494,000 after buying an additional 18 shares during the last quarter. AlphaCore Capital LLC lifted its stake in shares of Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after acquiring an additional 18 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in Intuitive Surgical by 2.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock valued at $390,000 after purchasing an additional 19 shares during the last quarter. Accredited Investors Inc. boosted its holdings in Intuitive Surgical by 1.9% in the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after purchasing an additional 19 shares during the last quarter. Finally, Second Line Capital LLC grew its stake in Intuitive Surgical by 3.4% during the 4th quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after purchasing an additional 19 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded down $0.82 during mid-day trading on Friday, hitting $512.18. The company had a trading volume of 2,181,892 shares, compared to its average volume of 1,675,828. The stock has a market cap of $183.57 billion, a price-to-earnings ratio of 79.90, a PEG ratio of 5.85 and a beta of 1.67. The firm's 50 day simple moving average is $526.57 and its two-hundred day simple moving average is $538.46. Intuitive Surgical, Inc. has a 12 month low of $413.82 and a 12 month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same quarter in the previous year, the company posted $1.50 earnings per share. Equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on ISRG. Truist Financial cut their target price on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Royal Bank of Canada dropped their price target on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Evercore ISI reduced their price objective on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a research note on Wednesday, April 23rd. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Finally, BTIG Research set a $560.00 target price on shares of Intuitive Surgical and gave the company a "buy" rating in a research note on Monday, April 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $588.95.

Insider Activity at Intuitive Surgical

In related news, Director Jami K. Nachtsheim sold 2,400 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the sale, the director now owns 6,371 shares of the company's stock, valued at $3,312,920. This represents a 27.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Robert Desantis sold 188 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the transaction, the executive vice president now directly owns 5,224 shares in the company, valued at approximately $2,695,113.84. The trade was a 3.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,998 shares of company stock worth $2,611,577 in the last ninety days. 0.70% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.